Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) EBITDA (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of EBITDA data on record, last reported at -$17.4 million in Q4 2025.

  • For Q4 2025, EBITDA rose 10.07% year-over-year to -$17.4 million; the TTM value through Dec 2025 reached -$72.8 million, down 35.82%, while the annual FY2025 figure was -$72.8 million, 35.82% down from the prior year.
  • EBITDA reached -$17.4 million in Q4 2025 per PLSE's latest filing, up from -$19.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$9.2 million in Q4 2022 and bottomed at -$19.4 million in Q4 2024.
  • Average EBITDA over 5 years is -$14.5 million, with a median of -$14.8 million recorded in 2021.
  • Peak YoY movement for EBITDA: skyrocketed 43.26% in 2023, then crashed 68.39% in 2025.
  • A 5-year view of EBITDA shows it stood at -$15.4 million in 2021, then surged by 40.34% to -$9.2 million in 2022, then dropped by 29.75% to -$11.9 million in 2023, then tumbled by 62.45% to -$19.4 million in 2024, then rose by 10.07% to -$17.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$17.4 million in Q4 2025, -$19.4 million in Q3 2025, and -$19.2 million in Q2 2025.